Aticaprant for Schizophrenia

(KAPPTIVATE1001 Trial)

This trial explores a new treatment called aticaprant for people with schizophrenia, assessing its safety and tolerability compared to a placebo. Researchers aim to determine successful participant enrollment and study completion. Ideal candidates for this trial include individuals diagnosed with schizophrenia for some time, stable on one medication, and receiving outpatient care from a psychiatric provider. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

You can continue taking your current antipsychotic medication, but it must be a stable dose of only one atypical antipsychotic. If you're on an antidepressant or anxiolytic, you can't change the dose within 8 weeks before the trial or during the treatment phase.

Research has shown that aticaprant is generally safe and well-tolerated. Earlier studies found that the most common side effects are mild, including headaches and diarrhea. Specifically, 11.8% of people taking aticaprant reported headaches, compared to 7.1% of those taking a placebo (a non-active treatment). Diarrhea was reported by 8.2% of aticaprant users, while only 2.4% of placebo users experienced it. Most reports indicate low levels of side effects. Although more research is needed, current findings are promising for safety.¹²³⁴⁵

Unlike most treatments for schizophrenia, which often focus on balancing neurotransmitters like dopamine, aticaprant works differently by targeting the kappa opioid receptor. This unique mechanism of action is believed to help manage symptoms such as hallucinations and delusions more effectively. Researchers are excited because this approach could offer a new way to alleviate symptoms for patients who don't respond well to existing medications, potentially leading to better overall outcomes.

This trial will compare Aticaprant with a placebo to evaluate its effectiveness for schizophrenia. Research has shown that Aticaprant may help reduce depression symptoms, especially when combined with other treatments. Studies have found that it decreases anhedonia, the inability to feel pleasure, which might be important for people with schizophrenia. Aticaprant blocks certain receptors in the brain, potentially improving mood and lessening negative symptoms. However, its specific effectiveness for treating schizophrenia remains under investigation. Most existing research focuses on its use for depression, with mixed results.¹³⁴⁶⁷